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In the memory of my grandfather Agr. Dr. Åke Nyhlén - 
 
who proved that nothing is impossible and that it is never too late. 
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ABSTRACT 
Background Postoperative pain treatment in women undergoing cesarean section (CS) needs 
to be effective to enable fast and smooth recovery without adverse outcomes and to improve 
breastfeeding and bonding between mother and child. It is also important that pain treatment 
should have minimal impact on the newborn 
 
The overall aim of this thesis was to investigate how to improve pain management in women 
undergoing cesarean section.  
 
Specific aims were:  
 To investigate if a single injection of bupivacaine with adrenaline close to the fascia 
could decrease opiate consumption and pain in patients undergoing CS in spinal 
anesthesia and whether the same treatment influences the need for opiates in women 
operated in general anesthesia (paper 1 and 3).  
 To study the overall incidence and risk factors for persistent pain after CS and to 
characterize the persistent pain, regarding intensity, body location and impact on daily 
life (paper 2).  
 To clarify whether oral oxycodone (OXY) can provide equal/better and safe 
postoperative pain relief after CS compared to intravenous morphine followed by oral 
codeine (IVM) (paper 4).  
 To study pharmacokinetic aspects of postoperative OXY treatment of mothers after CS 
and to investigate possible drug exposure through breast milk, including the effects on 
the newborn (paper 5). 
 
Methods and results:  
Study I: Two hundred and sixty women undergoing CS were randomized to receive injection of  
either 40 ml bupivacaine (2.5 mg/ml) with adrenaline (5 µg/ml) (n=130) or 40 ml saline 
solution (0.9%) (n=130), close to the fascia before closure of the wound. Morphine 
consumption, pain assessment by Numerical Rating Scale (NRS) and time to mobilization were 
recorded. Morphine requirements were significantly less for up to 12 h postoperatively and 
mean and maximum pain intensity lower during the first 6 h in the group receiving local 
anesthesia (p ≤0.05).   
Study II: A prospective follow up study of the women participating in study I. A questionnaire 
consisting of the Brief Pain Inventory (BPI) was posted to all women at 3, 6 and 12 months 
after surgery. Women rated pain intensity as well as interference with factors related to general 
function and quality of life. Women reported pain in one or more locations, in the CS surgical 
site as well as in other parts of the body. At 3 months 40% had pain and at 6 and 12 months 
27% and 21%, still had pain. CS on maternal request i.e. psychological indication as well as a 
first CS were significant (p ≤0.05) risk factors for persistent pain at 3 months. Severe 
postoperative pain in the immediate postoperative period (0-48 h) or undergoing a first CS were 
significant independent risk factors for the development of persistent pain up to 6 months after 
CS. Parameters related to quality of life such as sleeping difficulties were significantly impaired 
in women with persistent pain.  
Study III: A retrospective study (2008-2014) was conducted at the Karolinska University 
Hospital, Huddinge where medical records of women who underwent CS in general anesthesia 
were reviewed. After applying exclusion criteria 250 medical records remained. Information 
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about women receiving local anesthesia in the surgical wound, 20 or 40 ml 
bupivacaine/adrenaline (36 and 42 women in each group), were collected and data from women 
receiving no local treatment were identified and served as controls (n=172). A significantly 
lower morphine consumption during the 6 first postoperative hours was seen in patients 
receiving 40 ml local anesthetics when compared with controls (p ≤0.05) but no difference was 
seen for the 20 ml group or between treatment groups. 
Study IV: Eighty women scheduled for elective CS were recruited and randomized to receive 
extended release tablets and short acting OXY (n=40) or IVM (n=40). All patients received a 
multimodal therapy with ibuprofen and paracetamol and the opiates were administered as 
needed. Outcome measures were safety parameters for mother and child, opioid requirements, 
pain intensity by NRS, time to mobilization and time consumption to administer drugs. To 
evaluate safety for the newborns Apgar scores, acid base status in the umbilical cord, weight 
development and the Neurological Adaptive Capacity Score were used. A significantly lower 
postoperative pain intensity measured by NRS was observed 0-6 hours and 25-48 hours in the 
OXY group (p ≤0.05). Opioid consumption was significantly less in the OXY than in the IVM 
group 0-5 days postoperatively. Total time to administer analgesics was significantly shorter in 
the OXY group. There was a significant difference in common opiate related adverse effects 
between the two groups (3 women in the OXY group compared to 15 in the IVM/codeine 
group). No negative effects in the newborns related to opioid treatment were observed in either 
of the two groups.  
Study V: The material was obtained in study IV. Maternal blood and breastmilk were sampled 
at 24 and 48 hours and neonatal blood was collected at 48 hours postpartum. All samples were 
analyzed for OXY and the metabolites noroxycodone, oxymorphone and noroxymorphone. 
Detectable plasma levels of OXY and its metabolites were found in all women and even if there 
were small quantities of breastmilk detectable levels were found also here. In most cases there 
were low or non-detectable levels of OXY in the plasma of the neonates.  
 
Conclusions: A single injection of bupivacaine with adrenaline in the surgical wound decreases 
the need for rescue morphine postoperatively and was demonstrated to be a safe and effective 
pain management in women undergoing CS both in spinal and general anesthesia. Standardized 
postoperative treatment with oral OXY after CS was shown to be time effective and to give a 
better pain control, with lower opioid intake than a protocol using IVM/codeine, both as 
components of a multimodal analgesic regime. Our clinical data and the pharmacokinetic 
analyses support the view that OXY treatment is safe for mothers and neonates. As severe 
postoperative pain is a risk factor for long term pain the initial pain relief is crucial and we 
found that experiences related to quality of life were significantly impaired in women with 
persistent pain. We suggest that our findings can be of clinical importance, not least in women 
who have their CS performed in general anesthesia. 
 
Keywords: pain management, local anesthesia, cesarean section, morphine consumption, 
postoperative pain, persistent pain, risk factors, quality of daily life, multimodal treatment, 
oxycodone, codeine, newborn, safety. 
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List of abbreviations   
 
BMI 
BMT 
BPI 
b.w. 
CNS 
COX 
CS 
i.v. 
IVM/codeine 
NACS 
NICU 
Body mass index 
Breast milk transfer 
Brief pain inventory 
Birth weight 
Central nervous system 
Cyclooxygenase 
Cesarean section 
Intravenous 
Intravenous morphine and codeine 
Neurological and adaptive capacity score 
Neonatal intensive care unit 
NRS 
NSAID 
Numerical rating scale 
Non-steroidal anti-inflammatory drugs 
OXY 
PCA 
PK 
Oxycodone 
Patient controlled analgesia 
Pharmacokinetics 
SSC 
s.c. 
TAP 
WHO 
 
Skin to skin contact 
Subcutaneous 
Transversus abdominis plane blockade 
World Health Organization 
 
  
 
 
 
 
Definitions 
Multimodal treatment Treatment strategies which include a combination of 
different analgesic options such as regional techniques, 
opioids and non-opioid analgesics 
Numerical Rating Scale Numerical rating scale (NRS) is a numerical 10 cm scale 0-
10 where 0 is “no pain” at all and 10 “worst pain” 
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1 INTRODUCTION 
 
1.1 DEFINITION OF CESAREAN SECTION 
A cesarean section is a surgical procedure in which an incision is made through 
abdomen and uterus to deliver a baby. Cesarean section is also called caesarean 
section, C-section, CS. 
 
1.2 CESAREAN SECTION IN HISTORY 
There are many different explanations for the origin of the word cesarean. One 
explanation could be that it derives from the Latin verb “caedare", meaning to cut [1]. 
Cesarean section was performed when there was no more hope for the mother. Either 
she was dying or already dead or it was the last chance to save the fetus. There were 
also religious laws forbidding the fetus to be buried in the womb of the mother, the 
fetus was cut out and buried beside the mother [1, 2]. 
During the renaissance CS was conducted on medical grounds. The first known 
successful CS, according to legend, was performed in the year 1500, by the sow 
gelder Jacob Nufer. He did the CS on his wife and it was said that she gave birth to 
more children after the operation. The CS baby that was born on this occasion lived a 
long life and died at the age of 77 [1-3]. 
The first documented and corroborated CS was performed 1610 on a woman in 
Germany. The women survived the CS but died 25 days later from an infection. The 
baby boy survived the surgery and lived until the age of nine. 
The success of CS is defined from the outcome that the mother and fetus will survive 
for at least a month postoperatively. Successful CS was performed internationally for 
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the first time between 1826-1879, with one exception in 1792 when a CS was 
performed in the Netherlands on a women with a deformed pelvis [4]. 
 
1.3 CESAREAN SECTION TODAY 
1.3.1 Cesarean section rate worldwide 
A significant proportion of women giving birth undergo acute or planned CS. There 
are about 18.5 million CS deliveries performed every year globally (2008) [5]. 
 The rate of CS has increased worldwide during the past decades, in Sweden from 5% 
in the mid 70ths to slightly more than 17% in 2013 [6]. This rate continues to rise and 
is in Europe approximately 20% [7] and in USA 33% [8]. The CS rate in certain areas 
in South America is nearly 50%, but there is a difference in the rates depending on 
the presence of private birth clinics or not [9]. In 1985 the World Health Organization 
(WHO) stated: “There is no justification for any region to have CS rates higher than 
10-15%” [5]. A WHO report from 2010 states that countries with CS rates below 
10% are considered underusing, while countries with rates above 15% are considered 
to overuse. A rate between 10%-15% was considered normal and 14 countries out of 
137 were within this range. In the same report from 2010 the level of CS in Sweden 
was 17.3% with data from 2006. Brazil was in the top with a rate of 45.9% (2006) 
and Chad at the bottom with 0.4% (2004). Finland and Norway were slightly above 
16% and Denmark had a CS rate of 21% [5]. According to the report from the 
Swedish Society of Obstetrics and Gynecology (ARG-report), 2010, the largest 
percentage of increase in CS between the years 1995-2001 was within the group “CS 
before onset of labor”. Here an increase of 50% was observed in the group within 
single cephalic presentation. The frequency then remained unchanged for some years 
to increase in 2004 to 12.8% and reaching almost 14% in 2006. According to the 
ARG report risk factors for CS in the period 1995 to 2001 were primiparity, high 
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BMI, low education, smoking and being an immigrant. Moreover, it was seen that 
with increasing age the risk rose for CS. Women in the age group 35-40 were three 
times more likely to deliver by CS than those in the 20-25 year age group [10]. 
1.3.2 Indications for cesarean section 
The main reason for performing CS is an immediate threat to the life of mother and/or 
fetus. The CS can be performed within different time frames depending on degree of 
urgency (and local routines), from decision to action: Immediate, emergency or 
elective, the last one before onset of labor [11, 12]. The indications for CS varies 
from absolute medical indications like placental abnormalities, antepartum 
hemorrhage, uterine rupture, obstructed pelvis, acute fetal distress, protracted labor, 
maternal/fetal diseases, multiple pregnancy or fetal malpresentation, to relative 
indications including maternal request [13]. The most common indications for CS in 
Sweden 1995-2006 were disproportion/dystocia (newborn weighing >4500 gr; with 
34.2 %) and different kinds of fetal indications (31.7 %) [10]. 
 
1.3.3 Surgery – cesarean section 
1.3.3.1 Surgical technique 
The most used surgical technique in CS is the Joel-Cohen method, recommended by 
the WHO and discussed in the previously mentioned ARG report [10, 14]. The Joel-
Cohen method includes a lower transverse abdominal incision with non-closure of 
both layers of the peritoneum and intracutaneous suture in the skin. A commentary 
from the WHO Reproductive Health Library [14] covers two Cochrane reviews [15, 
16] which report that there are advantages for Joel-Cohen compared to the previously 
used Pfannenstiel incision with less postoperative morbidity, less need for analgesia, 
less blood loss, shorter surgery/delivery time and shorter hospital stay. With Joel-
Cohen the abdomen is mainly opened bluntly, after the first sharp incision fingers are 
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used to separate the tissues. This is considered the explanation for the 
abovementioned advantages for the Joel-Cohen compared to the Pfannenstiel 
technique.  
1.3.3.2 Intrathecal anesthesia 
Spinal anesthesia is the method of choice for CS. If an elective CS, a majority of 
women undergo the surgery with intrathecal anesthetic techniques, mostly spinal 
anesthesia with local anesthetics and today often with addition of an opioid [17]. 
General anesthesia is mainly used when under time pressure (e.g. fetal distress) or 
due to medical contraindications to intrathecal anesthesia. The epidural and spinal 
techniques are known as regional techniques because pain relief is limited to a certain 
anatomical region. One substantial benefit of intrathecal anesthesia is a conscious 
mother who has the possibility to have skin-to-skin contact with the baby 
immediately after the baby is born. The woman’s partner is also able to be present at 
the birth of the child. Another advantage of regional anesthesia is that relatively small 
doses of anesthetics are needed, with minimum side effects in the mother and the 
newborn. Intrathecal anesthesia is also a good start of effective pain relief, in 
combination with other drugs in the immediate postoperative period [18].  
 
1.3.3.3 Local surgery routines: pre-, peri- and postoperatively  
Preparations for CS in our setting follow strict procedures and premedication is 
normally given. According to local routines all women receive a bolus dose of 2 g 
paracetamol (Alvedon
®
) by oral administration one hour before any planned CS. 
Patients are fasting, get a peripheral venous catheter and a urinary catheter is inserted 
before going to surgery. The heartbeats of the fetus are monitored before surgery. 
Upon patient arrival in the operating theater all women get oral sodium citrate 
solution (30 ml). All patients receive a standardized intrathecal injection with 
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bupivacaine (Marcain
®
 spinal tung) followed by fentanyl (Fentanyl
®
) in a sitting 
position. As a rule the other parent or another accompanying person is present during 
the CS. Skin-to-skin contact between mother and child is initiated as early as 
possible, often already in the operating theater. The mother stays in the recovery 
room until full recovery from the intrathecal injection and pain is manageable. The 
woman is preoperatively instructed about how to use the Numerical Rating Scale 
(NRS) to evaluate pain and pain management. The scale goes from 0, no pain at all, 
to 10 worst imaginable pain. Pain is generally treated from NRS ≥4 until NRS ≤3. 
Mobilization starts from approximately 5-6 hours after surgery, with the women 
sitting on the edge of the bed, standing next to bed and walking around in the room. 
Early feeding with lunch and/or dinner the same day as surgery is practiced. Normally 
the patient is discharged from hospital 2 days after a CS. Pre-, peri- and postoperative 
routines are based on evidence and follow such recommendations as stated by the 
Royal College of Obstetricians and Gynaecologists [12]. 
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1.4 DEFINITION OF PAIN 
The definition of pain by the International Association for the Study of Pain (IASP): 
“An unpleasant sensory and emotional experience associated with actual or potential 
tissue damage, or described in terms of such damage” [19]. 
 
1.5 PAIN MECHANISMS 
Pain perception is multifactorial and a complex mixture of neural interactions that 
start with tissue damage (transduced and encoded by nociceptors), leading to 
activation of the ascending- and descending systems and a chain of events begins that 
involves both electrical and chemical activities. It is also activated by the influence of 
psychological and environmental factors [20-22]. Acute pain should therefore be 
viewed as the initiation phase of an extensive, persistent nociceptive and behavioral 
cascade most often triggered by tissue injury [21].  
Acute pain is present as long as the input is relevant and fades when the damaging 
stimulus is removed. Postoperative pain after CS consists of two different pain 
sensations. First the somatic pain from the wound and secondly the visceral pain from 
the uterine contractions. Mechanisms transducing these pains are somewhat different, 
in that the somatic pain is well localized, while the visceral pain is sensed as more 
diffuse pain in the somatic wound normally wanes within 1-2 days, while the visceral 
pain components last for a few days longer [23].  
When performing either the Pfannenstiel or the Joel Cohen incision the involved area 
is innervated by nerves from T11-T12. Nevertheless, the pain can also be derived 
from nerves outside this range as the skin is usually stretched and the internal organs 
manipulated during CS [17]. However, not only tissue damage but also psychological 
and sociodemographic factors are important factors behind patient’s perception of 
pain [24]. Kehlet reports in a review from 2006 that: “Theories about the 
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development of chronic pain have shifted from a biomedical model to a 
biopsychosocial one, in which pain is thought to be the result of an interaction 
between biological and psychological variables” [23]. The mental representation of 
pain is stored as both short-term and long-term memory and serves as an early 
warning avoidance system for future threats. The important issue is the patients’ 
perception/experience of pain [22]. 
 
1.5.1 Pain receptors 
The pain receptors are involved in the defense of the body from the surroundings by 
reacting to damaging factors as tissue injury, chemical influence, heating and cooling 
which can pose a potential risk [20]. An external noxious stimulus starts a cascade of 
events that leads to activation of peripheral sensory neurons, C- and Aδ- nociceptors. 
Both the A- and C-δ fibers responds to painful stimuli, initiates and mediates pain 
impulses from both somatic and visceral tissue. There are proportionally more Aδ 
fibers in the skin and somatic tissue as they are needed to localize the pain and to 
protect the injured body part in order for it to heal and get restored. While there are 
proportionally more C-δ found in the viscera. Aδ -fibers lead the "fast" immediate 
pain through the first stimulus, while Cδ -fibers account for the subsequent 
continuous pain [20, 25].  
A depolarization of the nerve cell occurs in connection with activation of the 
receptors, leading to an opening of sodium and calcium channels, resulting in sending 
a nerve impulse. At the same time inflammatory molecules as prostaglandins and 
bradykinins are released into the periphery and invoke an immune response activating 
and sensitizing the nociceptors and this also leads to a peripheral hyperalgesia 
reaction [26]. The definition of hyperalgesia is increased pain from a stimulus that 
normally provokes pain [19].  
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In conjunction with tissue damage growth factors are produced which are taken up 
and transported to the cell bodies in the dorsal root ganglia. This leads to an activation 
of receptors, which contributes to an increased sensitization of nociceptors and 
enhanced inflammation in the tissue. The result may be increased pain sensitivity and 
tenderness. This system warns, prevents, minimizes damage and promotes healing 
[25]. C- and Aδ -fibers mediate nociceptive information from both visceral and 
somatic sites to the spinal cord via the dorsal roots to the horn of the spinal cord 
where they will have a first synaptic contact with secondary neurons that are 
principally located in the lamina I, II and V. Second-order neurons ascend to higher 
centers via the contralateral spinothalamic and spinoreticular tracts. The thalamus is 
the key area for processing somatosensory information. From the thalamus in the 
brain a transmission and processing occurs in the cortex and the limbic system is 
responsible for the emotional-affective component of pain. The pain signals are 
projected to areas of the somatosensory cortex as responsible for the conscious 
sensory-discriminative part of the pain experience [25]. Marchand (2008) describes 
the interaction between pain and brain: “Pain can only be experienced when 
nociceptive afference reaches the cortex. Pain is a complex perception requiring 
central nervous system (CNS) activity” [25].  
The entire process can be summarized as follows: As pain is a dynamic phenomenon, 
the nociceptive signal will be modulated at multiple levels of the CNS before pain is 
fully perceived. The modulation of the nociceptive signal starts at the periphery and 
involves several CNS structures, including excitatory and inhibitory mechanisms 
from the brainstem, the autonomic nervous system, and the cortical structures 
responsible for the emotional and cognitive aspects of pain perception [20, 25]. 
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1.6 CHRONIC PAIN/PERSISTENT PAIN 
Definition of chronic pain or persistent pain by IASP is pain that has lasted for three 
months or more, “persisted beyond the normal tissue healing time” [27]. Behind the 
prolonged pain are partially permanent changes, both in the neural pathways that 
mediate pain and in other tissues [28]. Ten to 50% of individuals develop persistent 
pain after acute postoperative pain in connection with common surgeries, and 2 to 10 
percent of all persons with persistent pain experience the pain to be severe. On this 
basis Kehlet and coworkers state that persistent postsurgical pain is a major 
underrecognized clinical problem [23]. 
Several risk factors for persistent pain that have been suggested: preoperative pain for 
more than one month, severe postoperative pain, nerve damage during surgery, 
psychological anxiety and vulnerability [23, 29, 30]. Not much is known about the 
underlying mechanism behind persistent pain. Central sensitization and/or 
dysinhibition of central pain inhibitory mechanisms involving endogenous morphine 
are considered as the two dominant mechanisms of dysfunctional pain [31]. Reuben 
describes this phenomenon in a review article from 2007: It is now known that 
nociceptor function is dynamic and may be altered after tissue injury, which may 
contribute to persistent pain. Repetitive stimulation of small diameter primary 
afferent fibers generates a progressive increase of the action potential discharge and 
increased excitability of both peripheral and CNS neurons, an event termed central 
sensitization or "windup” [30].  
Central sensitization can be developed already after a few hours of peripheral 
nociceptive stimulation, leading to pain prolonged beyond a duration expected after 
an acute event. An early hyper-excitability is often temporary if the peripheral 
nociception ceases. With continued or repeated peripheral nociception the risk of a 
permanent sensitization increases. A prolonged central sensitization has the capacity 
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to lead to permanent alterations in the CNS [23, 30, 31] where the end point is severe 
postsurgical pain, that is unresponsive to many analgesic and/or strategies [30]. 
Persistent postoperative pain is a well-known consequence not only after major 
surgeries as limb amputation, breast and thoracic surgery but also following other 
common types of surgery, e.g. groin hernia repair [23]. Several reports demonstrate 
that postoperative pain management is insufficient among 50-70% of patients 
undergoing different types of surgery and as mentioned before there is substantial 
evidence that severe postoperative pain may lead to an increased incidence of chronic 
pain [32, 33]. Breivik and coworkers found, in a large European interview study with 
more than 46.000 respondents, a prevalence rate of chronic pain between 14-40% in 
various countries. Nineteen percent of adult Europeans suffer from long lasting pain 
of moderate to severe intensity seriously affecting their daily activities and social life. 
Breivik states that “chronic pain is a major health problem in Europe” [34]. High age, 
ethnicity, education, social background, as well as depression and anxiety are 
associated with a high prevalence for chronic pain [25, 34-36]. The connection 
between unsatisfactory pain management and persistent pain is close. Kainu et al. 
compared persistent pain one year after CS and vaginal birth and found that it was 
more common with pain after CS than after vaginal birth [37]. Schytt et al. reported 
that more than one third of the women suffered from pain for up to two months after 
CS [38]. Ineffective pain management postoperatively after CS seems to increase the 
risk for persistent pain and correlations have been demonstrated between severe 
postoperative pain and persistent pain [24, 37, 39, 40]. Loos et al. reported that 
chronic pain was common both after hysterectomies and CS done by Pfannenstiel 
incision [39].  
 Chronic pain following CS was also described in the study by Nikolajsen and 
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coworkers and about one third of the patients (223 out of 690) experienced pain two 
years after the surgery [40].  
 
1.7 PAIN MANAGEMENT IN HISTORY 
Since ancient times, man has found different ways to treat pain and illness. Drugs 
used for decades are used even today, in various forms. 
Herbs have always been used for medication and as painkillers. Mandragora root – 
mandrake, poppy seeds and juice, juice of poplar trees and the bark of the willow for 
example have been used as remedies [41]. 
 
Opium has been used for decades for all kinds of pain and health concerns as cough, 
insomnia and diarrhea. Laudanum was invented in the 17th century and is a tincture 
of opium and alcohol that contains almost all of the opium alkaloids. Many of the 
medicines were used for pain and sometimes also for cough. It was used alone or 
mixed with different kinds of ingredients as e.g. pearl, musk, pepper, nutmeg and 
saffron [42]. 
Laudanum was a milestone in pharmacotherapy and a very popular remedy in the 19
th
 
and 20
th
 centuries. It was an ingredient in many patent medicines and was used for 
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most health issues as insomnia, bodily system failure, menstruation cramps, cold and 
cardiac diseases, both in adults and in children [41, 42]. 
 
1.7.1 A new era 
Around 1820 the German scientist Sertürner isolated a crystalline drug out of opium 
that he named morphium after the Greek god of dreams, Morpheus. In 1828 the 
Oxford English Dictionary has the first citation in English: “morphine is the narcotic 
principle of opium” [43]. Morphine has been industrially produced since early-mid-
1800.  
Before the time of efficient pain killers skilled surgeons operated rapidly without 
sedative. Some doctors started to investigate how to achieve pain relief by using 
sedative gases, e.g. ether and chloroform [41, 44]. In 1848 a British obstetrician, 
James Young Simpson, proposed chloroform to be used in childbirth and surgery 
[41]. Analgesia during surgery was something new in the mid-1800, was 
revolutionary in modern medicine, but was not received entirely positive. Both in 
medicine and in religious circles, it was considered that pain made man strong. It was 
considered unethical to operate on unconscious people and it broke the law of God. A 
woman should give birth in pain to get the insight that she would sacrifice herself for 
her child [44]. John Snow invented devices for administration of ether and 
chloroform and the attitudes of the physicians about using chloroform during 
childbirth changed when he anesthetized Queen Victoria when giving birth to Prince 
Leopold in 1853 [41]. 
A new era of pain management began in 1850 when needles and syringes were 
invented and morphine could be injected subcutaneously (s.c). In 1898 heroin was 
synthesized from morphine and became a very popular remedy for “everything”, i.e. 
toothache, headache but most of all as cough remedy. It was said not to have as 
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adverse effects as morphine [41, 44]! Through successful research new opioid 
analgesics were developed. Semisynthetic and synthetic derivatives of morphine were 
developed, for example oxycodone (OXY) in 1915 and pethidine in 1939. In 1953 P. 
Janssen developed fentanyl, a drug that was 40 times more active than morphine, and 
later on came even stronger drugs, one of them sufentanil [41]. 
Regional nerve blocks with both alcohol and procaine were used regularly from the 
end of the 19
th
 to the beginning of the 20
th
 century. World War II opened up new 
opportunities to study and work with the pain of wounded soldiers. In the late 40's it 
was realized that pain was influenced not only by physical problems but also by 
emotional and cognitive factors [44]. 
In 1965 Melzack and Wall presented their “Gate Control Theory” dealing with the 
transmission of pain sensations from the periphery to the brain. This was described as 
the path of pain from the body to the brain being controlled by the spinal cord, which 
admits only a limited amount of pain impulses through different ports that are opened 
or closed [44]. 
Coca leaves or its synthesized substance cocaine was developed as a nerve block in 
the shift between the 19
th
 and the 20
th
 century. Local s.c. infiltration with cocaine as 
one of the ingredients was described for the first time in the beginning of the 20
th
 
century [41]. The characterization and description of the function of opioid receptors 
and nociception in the 1970s was another milestone in the continuing work for 
effective pain relief techniques. Research about administration of opioids in the 
subarachnoid space gave results and intrathecal (spinal and epidural) administration 
of opioids was used clinically from the 80’s. Though morphine administration in the 
spinal cord was mentioned already around 1910, the improvement of local anesthetics 
continued throughout the 20
th
 century with bupivacaine synthetized in the late 50’s. 
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From the beginning of the 20
th 
century and onwards new analgesic techniques were 
developed, including regional blocks and neurosurgery, to achieve pain control. A 
momentous event for the treatment of chronic pain was 1983 when the sustained 
release tablet MS Contin
® (morphine sulfate) became available. In the 90’s 
transdermal administration was found to be safe and effective both for cancer and 
non-cancer pain. This was later on followed by different ways to administer opioids 
and other substances, e.g. trans-mucosal (lollipop), intranasal or sublingual 
administration [41]. From the end of the 19
th 
century, based on the knowledge of their 
active substances, potent and well-functioning drugs were developed. Salicylic acid 
was for example synthesized out of willow bark and was found to be useful in 
patients with rheumatism and neuralgia. Salicylic acid was developed to 
acetylsalicylic acid, “Aspirin”, an even well-functioning synthetic drug. Starting from 
here the development of non-steroidal anti-inflammatory drugs (NSAIDs) continued 
[41]. The understanding of the entire mechanism of action behind NSAID medication 
was not explained until the 70’s. Further research led to the next generation of pain 
killers. When the COX-1 and COX-2 enzymes were identified new drugs were 
developed without the side-effects of NSAID drugs. Patient controlled analgesia 
(PCA) was introduced in the 60’s in obstetric patients in labor and patient controlled 
epidural analgesia was also developed for obstetric patients and for post-operative 
pain management [41]. 
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1.8 PAIN MANAGEMENT TODAY -  
IN ALL SETTINGS INCLUDING MATERNITY CARE 
1.8.1 Basics regarding analgesics 
Bridgestock and coworkers describe the benefits of multimodal analgesia “As the 
transmission of pain involves many different receptors within the peripheral and 
central nervous system, multimodal analgesia is best employed to optimize pain 
control and limit side effects” [20]. A multimodal approach for analgesia uses a 
combination of drugs with different mechanism of action, with the aim to optimize 
pain management and to minimize adverse effects through additive and synergistic 
drug actions [17]. 
Pain medications, sometimes called “pain killers,” usually work by targeting the 
receptors and neurochemical mediators. Medications can only offer a short-term 
relief, to eliminate the pain it is necessary to treat the underlying causes [20, 25]. 
 
1.8.2 Analgesic administration in present time 
A combined approach is generally considered to be the best way to control pain [17, 
45-47]. Two reviews report that a common way to achieve control of postoperative 
pain after CS is by systematic and/or neuraxial morphine. Morphine is mentioned as 
the “golden standard”. The reviews conclude that the use of several analgesics of 
complementary mechanism of action, known as multimodal or balanced analgesia, is 
required to achieve a satisfactory and effective pain relief with few side effects [17, 
45]. Kehlet states “with several combination regimens there is concomitant reduction 
of side effects owing to the lower doses of the individual drugs and differences 
between drugs in side effect profiles” [48]. In all settings the avoidance of adverse 
effects are important, but it is even more important after CS due to the need to care 
for and bond to the new baby and the wish to breastfeed [17, 49]. 
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Lavoie and Toledo summarize the options for post-CS pain management [17]: 
 Neuraxial analgesia (spinal, epidural and the combination spinal/epidural) 
with long-acting opioid.  
 Systemic opioid analgesics (intravenous, intramuscular and oral opioids). 
 Non-opioid analgesics (nonsteroidal anti-inflammatory drugs, paracetamol). 
 Peripheral nerve blockades. 
 Non-pharmacologic analgesic options (e.g. transcutaneous nerve stimulation 
(TNS) or massage). 
 
1.8.3 Systemic opioid analgesics 
Intravenous and s.c injections have previously been a routine way to relieve pain 
postoperatively. The advantages of these methods are that they are simple, 
inexpensive and have a long tradition in health care. The disadvantages are that it 
often requires repeated injections for an optimal pain relief and any delay in 
administration of the drug can cause frustration as the pain increases [17, 46]. Either 
the patient waits too long, as she doesn’t want to disturb the staff [50, 51], or it takes 
time for the staff to respond to the patients request. Within the current tightened 
resources in staffing, it is usually a congested workload in the wards which can result 
in a delay for medical help. The time from asking for rescue medication until 
administration of the i.v., intramuscular or s.c. injection can be long. The time for the 
drug to reach the target tissue must also be included when summarizing the time until 
alleviation of pain [17, 46]. There is an increased risk that pain has intensified, and 
greater efforts are needed to control the pain. There are large inter-individual 
variations in the uptake of the opioids and this can lead to difficulties in finding the 
 24 
 
correct dosing, resulting in an adequate pain relief. This may lead to an increased risk 
for adverse effects [46]. 
Many of the disadvantages associated with parenteral administration can be avoided 
by using patient controlled analgesia (PCA). Opioids are administered i.v. by a device 
and pain relief is given intermittently by demand from the patient. The positive effect 
is a more constant drug administration with fewer episodes of breakthrough pain 
which reduces the risk for persistent pain. The interindividual variability is less with 
continuous administration, this is important regardless of patient category. PCA may 
not be the optimal method for administration of analgesics in all postoperative 
settings. For one, it requires education of staff and patients. Another limitation with a 
PCA device in a maternity setting is that it might be an obstacle in the care of the 
baby and although it increases the autonomy in terms of pain control it also reduces 
the mothers’ flexibility as the device has to be carried around [46]. One way to 
improve analgesia and to act on recommendations for multimodal treatment is to 
administer drugs orally. Different kinds of opioids can be given as long or short 
acting tablets or capsules.  
 
1.8.4 Non opioid analgesics 
NSAIDs are effective in the treatment of visceral pain, reduce the inflammatory 
process associated with surgery and affect the nociceptive responses associated with 
acute pain. Secondly, NSAIDs improve the effect of systematically or neuraxially 
given opioids and decrease opioid related adverse effects due to their opioid sparing 
effect [17, 46]. Paracetamol is often used in combination with morphine and/or 
NSAID medication, although different studies have failed to prove the effect of 
enhanced effectivity by adding this drug [17]. There have been concerns against 
NSAID because of potential gastrointestinal side effects and dysfunction of platelets. 
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The cyclooxygenase (COX-2) inhibitors are also used in post CS pain management 
and they may be an alternative choice as they do not inhibit platelet function [46]. 
 
1.8.5 Neuraxial analgesia 
Neuraxial anesthetic techniques are common ways not only to give anesthesia during 
surgery but also to prevent post-cesarean pain. The function depends on two different 
mechanisms, the administration of the drug (epidural or spinal) and the lipid 
solubility of the administered drugs. Sufentanyl and fentanyl are drugs with high lipid 
solubility, “fast in and fast out”. Morphine on the other hand is a hydrophilic opioid 
and has a slow onset and a longer duration of analgesia. The best way to treat post-
cesarean pain with neuraxial anesthetics is using a combination of lipophilic and 
hydrophilic opioids. This provides a rapid onset of analgesia with long duration. 
There is an advantage for neuraxial administration of drugs compared to systemically 
given drugs as smaller amounts are needed with neuraxial administration [17, 46]. 
Lavoie and Toledo did a survey of 75 publications on post CS delivery pain and pain 
mechanisms and summarized that “in the absence of contraindications, intrathecal 
morphine should be considered the gold standard for providing prolonged 
postoperative analgesia” [17]. 
 
1.8.6 Peripheral nerve blockades 
Transversus abdominis plane blockade (TAP) blockades have been put forward as 
efficient and complementary therapies. TAP is considered to be the most common 
form of peripheral nerve blockade. The blockade is done with local anesthetics into 
the abdominal wall. The technique is used in connection with CS but there are 
conflicting results on the benefits of the treatment [52-55].  
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1.8.7 Local anesthetics 
To a great extent pain experienced after CS arises from the surgical wound. One 
simple way to approach the postoperative pain is to combine local anesthetic, as 
wound infiltration, with intravenous morphine. In the guidelines presented by The 
National Institute for Health and Clinical Excellence in UK (NICE) wound 
infiltration at CS is suggested as an efficacious alternative to other regimes [12]. 
Several studies support this view and in a review of 20 studies, by Bamigboye and 
Hofmeyr, the conclusion was that local pain management decreased the consumption 
of morphine postoperatively in women who had CS under spinal anesthesia [56, 57]. 
When proven to be efficient the use of local anesthetic as pain management would 
decrease the risk for opioid related side-effects as nausea, vomiting and dizziness [56, 
58]. It would also decrease the risk for drugs passing over to the baby. Local 
infiltration of an anesthetic drug is a commonly used method in different settings 
[59]. Rapid onset and short acting local anesthetics e.g. lidocaine and carbocaine are 
often combined with adrenaline, resulting in a nearly doubled duration of anesthesia 
through vasoconstriction of the arteries [59]. This is due to that the resorption of the 
local anesthetics is delayed. Bupivacaine and ropivacaine are in contrast to lidocaine 
long-acting substances and in this case the function of adding adrenaline is to reduce 
bleeding by vasoconstriction [59].  
Most common is infiltration in the surgical wound with PCA catheters [46, 56, 58, 
60-62]. Givens et al. found that the morphine consumption after CS was significantly 
lower in a group receiving local infusion of bupivacaine in the wound than in a 
control group receiving saline. The catheter in the incision was left in space for 48 
hours. According to the authors one weakness in this study was that the catheter itself 
could irritate the tissues which might lead to increased pain [61]. Fredman et al. are in 
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agreement with the study by Givens but they also mentioned that catheter-associated 
infections could be a risk and had safety concerns about pain pump failure [60]. 
The evidence on the benefits of a single dose of local anesthetic in the cesarean 
wound is limited and contradictory. Trotter et al. found that bupivacaine infiltration in 
the surgical site reduced the amount of rescue morphine post CS in women operated 
in general anesthesia, but only when the dose was adjusted for the women’s weight 
[63]. 
 
1.9 PHARMACOKINETICS AND PHARMACODYNAMICS 
Pharmacokinetics (PK) describes what the body does to the drug and 
pharmacodynamics (PD) what the drug does to the body. 
A popular scientific way to describe PK is “A chemical cannot be a drug, no matter 
how active nor how specific its action, unless it is also taken appropriately into the 
body (absorption), distributed to the right parts of the body, metabolized in a way that 
does not instantly remove its activity, and eliminated in a suitable manner – a 
compound must get in, move about, hang around, and then get out” [64]. 
The acronym ADME describes the different phases the drug takes through the body. 
Absorption of the drug by the body. The site of administration of the drug can vary 
and depends on the urgency and the dose of the drug affects the drug's path to action 
[65]. An i.v. injection is distributed directly into the venous circulation and isn’t 
subject to first pass elimination as a drug administered orally [64, 65]. Bioavailability, 
dose and dosing interval control the drug concentration level in the body and hence 
the effect of the drug. The term bioavailability describes the amount of a given dose 
that enters the systemic circulation. When a drug is administered i.v. the 
bioavailability is 100%. If drug administration is oral (the most common way) the 
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compound must be absorbed in the gastrointestinal tract. The drug will pass through 
the liver and will to varying extent be deactivated, and in some cases activated, before 
entering the body circulation. Modification of the orally administered drug in the liver 
is called first pass effect and in general the availability of the drug taken by mouth 
compared to i.v. injection will be considerably less [64-66]. 
Many factors determine bioavailability: the route of administration, if taken together 
with food, interactions with other drugs, diseases, problems with internal organs, age 
and genetics are some of those factors. Distribution volume describes the proportion 
of bioavailable dose and plasma concentration of the drug. Clearance (liver- and 
kidney clearance) explains the body's ability to eliminate a drug and describes, for 
example, how much blood volume that is purified from the drug and is described in 
the unit ml/min. Another term is elimination half-life and it describes the time 
required for the concentration of the drug to reach half of its original value. It is 
dependent on both the volume of distribution and the clearance. Cmax is a term that 
describes the peak plasma concentration of the drug after administration. Tmax stands 
for time to reach Cmax [64, 66].  
Distribution through the fluids and different body tissues. Water and lipid solubility 
of the drug affects how the drug migrates through various biological barriers and 
becomes distributed in the body. Lipophilic drugs tend to be distributed into the body 
tissues to a greater extent than water-soluble drugs [64, 65]. Lipophilic drugs, like 
opioids, are easily distributed to all tissues, including nervous tissues and the brain 
and may also accumulate in the tissue [67]. 
Metabolism - recognition of a foreign substance and starting a conversion of the drug 
to its metabolites. A drug is often active in its primary form but in some cases the 
drug undergoes a metabolic activation, as in the case of activation of codeine to 
 29 
 
morphine via CYP26D, and in some cases the drug is to varying extent deactivated 
already at the first step of metabolism. An active substance/metabolite will reach the 
therapeutic target to achieve the effect. The end point in the metabolic process is to 
eliminate the substance via bile or urine and in general this process involves steps 
converting the drug into a less lipophilic compound that is easier to excrete [67]. 
The metabolism or biotransformation of the drug is most often mainly proceeded in 
the liver but metabolism can also take place in other sites, as the kidneys, intestines, 
lungs and skin. The metabolism in the liver involves various enzymes and takes place 
through two major pathways. Phase I modification reactions include oxidation, 
reduction and hydrolysis, whereas phase II reactions involve conjugation with e.g. 
glucuronic acid or sulfate (transformation to hydrophilic substances) [64, 65]. Most 
opioids given orally undergo a first pass metabolism in the liver before reaching the 
systemic circulation, thereby decreasing the bioavailability of the drug [67]. 
The enzymes in the cytochrome P450 (CYP450) group are involved in the phase I 
oxidative reactions, involving the biotransformation of drugs as well as hormones. 
They have a key role in the biotransformation of drugs and are present in most tissues 
in the body [67, 68]. CYP2D6 alone is responsible for the metabolism and 
elimination of approximately 25% of all drugs and is involved in the metabolism of 
both codeine and OXY. CYP2C9 metabolises ibuprophen and CYP2E1 and CYP3A4 
metabolise paracetamol [67]. 
Elimination of the substance and how it is removed from the body [64]. This 
elimination is dependent on metabolism as previously indicated. The liver is 
important for elimination and transformation of any highly lipid soluble drug to more 
hydrophilic metabolites and the biological function is to facilitate excretion through 
bile or urine. Hydrophilic drugs on the other hand primarily depend on renal function 
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for elimination [64]. The ability to bind different drugs differs between the various 
body tissues. The effect of the drug occurs when molecules attach to different 
receptors.  
 
1.9.1 Opioid metabolism  
1.9.1.1 Mechanisms of action 
Opioid receptors are mainly located in the nervous system where the drug effect is 
most effective. The receptors are divided into three categories, μ (my), k (kappa) and 
δ (delta) receptors. The opioid receptors connected to the compounds included in this 
thesis are primarily μ (my) agonists as are most analgesics. They are mainly located 
in the CNS, brain and spinal cord as well as in the intestine. 
The CYP2D6 enzyme is involved in bioactivation of codeine and in hydrocodone 
metabolism whereas CYP3A4 is a key enzyme in the metabolism of oxycodone. 
Morphine is metabolized in the liver by phase 2 conjugation - glucuronidation [67]. 
The large variation of opioid effects can be explained by that every individual opioid 
has its own specific relationship to the various opioid receptors. Opioid 
transformation results in both active and inactive metabolites. Sometimes the active 
metabolite is more potent than the parent drug.  
 
1.9.1.2 Oxycodone  
Oxycodone is a lipophilic drug. The liver enzyme CYP3A4 is the main metabolizer 
and converts OXY to noroxycodone. CYP2D6 is also involved in the metabolism and 
converts a small amount of OXY to oxymorphone. The metabolic pathways for OXY 
are initially phase I events and the elimination of noroxycodone, oxymorphone and 
noroxymorphone also involves phase II metabolism via glucuronidation [69]. There is 
no inactive form of OXY and the active forms include oxymorphone and 
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noroxycodone [67, 69]. The opioid effect is mainly mediated by the parent drug OXY 
and it is questionable whether oxymorphone has any significant effect in pain relief 
[67]. Klimas recently reported that OXY itself is responsible for the analgesic effect 
and even if oxymorphone and noroxymorphone have a higher affinity to μ-receptors 
the concentration of the metabolites is low [70].  
 
A major difference between oral OXY and morphine is the oral bioavailability, for 
OXY more than 60% [69]. 
 
1.9.1.3 Morphine  
Morphine is a lipophilic drug. The metabolic pathway for morphine is a phase II 
event and glucuronidation yields 2 metabolites with different efficacy, the inactive 
metabolite normorphine and the active metabolite hydromorphone. The mean oral 
bioavailability for morphine is round 30% but varies between 10 and 50% [67]. 
 
1.9.1.4  Codeine  
Codeine is a prodrug that after CYP2D6 mediated activation is converted to 
morphine. Codeine’s inactive form is norcodeine and the active form is hydrocodone. 
The activity of the CYP2D6 enzyme is genetically determined which can lead to an 
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unpredictable bioavailability of codeine [67].  
 
 
1.9.1.5 Genetic factors 
Genetic factors determine the activity of CYP2D6 and toxicity has been reported in 
CYP2D6 ultra-rapid metabolizers as they convert codeine to large amounts of 
morphine, whereas slow metabolizers are unable to form the active metabolite [67]. 
Most women have a “normal” CYP2D6 activity (“rapid metabolizers”) but 
approximately 5% of Swedish-born women (approx. 5-10% of Caucasians) convert 
virtually no codeine to morphine as they possess a defect allelic variant of the 
CYP2D6 gene, leading to non-existent effects on pain [67, 68]. One percent of the 
Swedish-born population (1-7% of Caucasians) carries the duplicated or 
multiduplicated CYP2D6 allele, associated with very high conversion ability that can 
lead to toxicity and side effects [68, 71]. In some populations, such as women from 
Ethiopia and Eritrea, the proportion of ultra-rapid metabolizers is as high as 29% [67, 
68, 72].  
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1.10 INTERACTION BETWEEN MOTHER AND CHILD IN CONNECTION 
WITH CESAREAN SECTION 
There is a difference when taking care of a newborn child after a vaginal delivery 
compared to after a CS. In the latter case, the woman has not only become a mother 
but also needs to recover from a major abdominal surgery. Moreover, if it has been an 
emergency CS, in general anesthesia, the woman wakes up without knowing what has 
happened to her and to her baby. This may enhance the risk for fear and anxiety, 
increasing the already existing postoperative pain [46]. Therefore it is of paramount 
importance to optimize post-cesarean pain management to avoid disturbed bonding 
and interaction between mother and child [46, 49, 57, 73, 74]. 
Skin-to-skin (SSC) contact is important, the key message in the review by Stevens 
and coworkers says “skin-to-skin contact may reduce maternal pain, improve 
parent/newborn contact and communication, and keep the mother and newborn 
physiologically stable” [75]. Some studies also demonstrate that SSC may reduce 
postoperative pain [76, 77]. 
This assumes that all is well with mother and newborn. If the baby for some reason 
ends up in the NICU it is even more important with effective pain management to 
give the mother possibility to visit and stay with her newborn baby. It is therefore of 
importance that the pain relief is not only efficient but also easy to administer, not 
restricting the mother's ability to move [46]. 
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1.11 BREASTFEEDING AND CESAREAN SECTION 
 
 
 
Several studies have shown that initiation of breastfeeding and the breast milk 
transfer (BMT) [78] often is delayed after CS and more breastfeeding problems occur 
after CS when compared with vaginal delivery [75, 79, 80]. Zanardo (2010) reported 
that there was a delayed first breastfeeding and a lower rate of breastfeeding up to six 
months associated with CS. There was also a lower prevalence of breastfeeding in the 
delivery room after CS compared with vaginal birth. No difference in breastfeeding 
rates was observed between elective and emergency CS [81]. Evans and coworkers 
found that BMT to the baby was delayed after CS compared to vaginal birth but the 
difference was no longer present six days after birth. The babies’ milk intake was 
estimated to be 4 ml/kg b.w. on day one, increasing to 44 ml/kg b.w. on day 4. It took 
longer for the baby to regain birth weight in the CS group compared to the vaginal 
birth group, at day six 40% in the vaginal birth group had regained birth weight 
compared to 20% in CS group [78]. 
It has also been reported that duration of breastfeeding is shorter after CS compared 
with vaginal birth [82]. Mothers delivering their babies with CS had a more stressful 
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attitude to breastfeeding compared to women with vaginal births. When they were 
asked at three and nine months postpartum the CS group reported more complicated 
breastfeeding than women in the vaginal birth group [83].  
 
 
1.11.1 Drugs and breastfeeding 
It is important with safe and effective pain relief post CS as the analgesic passes over 
to the baby when the drug is excreted through breast milk. Approximately 90% of all 
women giving birth have been shown to take some kind of drugs during the first week 
postpartum [84].  
Ito and Lee describe the mechanism of drug transfer into milk [84]. Many factors are 
involved in the process, such as plasma protein binding, ionization, the drug 
lipophilicity, molecular weight and the drug’s pharmacokinetics in the mother. 
Generally low molecular weight and low plasma protein binding, high lipophilicity 
together with cationic properties facilitate increased excretion of the drug into the 
milk. The lower pH in breast milk than in plasma is an important factor for transfer of 
basic drugs to breast milk [85]. The drugs diffuse through the mammary gland 
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epithelia and it is clear that carrier-mediated processes are involved with excretion of 
several drugs into milk [84]. 
Milk to plasma/serum drug concentration ratio is the ratio between drug concentration 
in milk and maternal plasma/serum. It is a time-dependent parameter and is 
influenced by factors as changes in the composition of the milk and maternal 
pharmacokinetics. It was proposed that the ratio can be predicted from the 
physiochemical characteristics of those drugs that are mainly transferred into milk by 
passive diffusion [84]. The fact that the milk changes over time from the first milk 
colostrum to transitional and mature milk must also be considered and there are 
composition changes within a feeding from foremilk to hindmilk. This contributes to 
a time- and phase dependent variation of drug excretion into milk [84]. 
For many drugs there are lower concentrations in breastmilk than in blood and even 
when exclusively breastfeeding the transfer of drug to the baby corresponds to only 
0.5-2.0% of the daily dose to the mother, for most drugs being a low dose doing no 
harm to the newborn [84]. The level of exposure depends on the milk to plasma ratio 
and on the rate of clearance. Drugs with a low rate of clearance are associated with a 
higher level of exposure of the newborn. Even if the milk to plasma ratio is high but 
the clearance rate of the drug is rapid the exposure of the newborn will be limited. Ito 
describes it as “the rate of drug clearance by the infant is more important in 
determining the degree of exposure than is the milk-to-plasma ratio of the drug” [86].  
He also states that a safe value is characterized as transfer of drug through breast milk 
leading to no more than 10% of the therapeutic dose for infants (or of the therapeutic 
dose to adults, standardized by weight if the infant dose is unknown).  
For the opiates codeine, morphine and OXY it is a well-known fact that they 
accumulate in breast milk. The breast milk to plasma ratio for codeine has been 
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reported to be 1.3-2.5:1 [87], for morphine 2.45:1 [88] and for OXY 3.2:1 [89]. 
Consequently there is a risk for accumulation in the nursing baby. Another aspect that 
can be considered is the lower capacity to metabolize opioids in the newborns. The 
half-life of morphine is much longer in the neonatal period than in adults, due to a 
low capacity for glucuronidation [90] and the elimination of OXY is impaired in the 
newborn due to low capacity for N-demethylation via CYP3A4, which is a major 
metabolic pathway [91, 92]. Furthermore, minor amounts of OXY are metabolized 
via CYP2D6 by O-demethylation and the fetal levels are low also of this enzyme 
[91].  
Several reports are available regarding serious effects of opiate exposure, especially 
in children born to those mothers treated with codeine who are ultra-rapid 
metabolizers [93, 94]. Extremely high exposure to morphine has been detected in 
some of these children and Koren et al. reported about one fatal case with a mother 
taking codeine for almost two weeks and where the baby died [95]. Due to the more 
constant bioavailability of oral OXY than for oral morphine and because metabolism 
of codeine is extremely variable OXY has become an interesting alternative for 
women postoperatively after CS. Some reports suggest that there are risks when 
giving breast-feeding women OXY for a prolonged period but for short-term use no 
such risks have yet been identified [89, 96]. The previously mentioned low intake of 
milk during the first days after CS can be assumed to contribute to these observations 
and risk assessments [78]. Taken together, the general view is that the risks related to 
opiate exposure in breast fed infants are extremely low when the drugs are given only 
for a short period after delivery [89, 92, 96]. 
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1.11.2 Interference and risks with ineffective pain management  
Pain management is a subjective action, where the decisions very much depend on the 
person that administers the medication [50]. At the maternity ward the demands on 
the staff are complex as accurate pain assessment and individual adjustment of 
treatment is extremely important in this group of patients [17, 46, 47]. New mothers 
are reluctant to feel sleepy or to have pain that would lead to a restriction in taking 
care of their baby. They are also keen to protect the baby from drug effects through 
the breastmilk which sometimes lead to that they do not always ask for the analgesia 
they need. Any medication given to this group of patients should be effective and, if 
possible, free from side-effects as it also interferes with a second part, the newborn 
baby [73, 97]. Effective pain management is an important issue after surgical 
interventions. The association between early mobilization, decreased risk for 
complications and patient satisfaction with good pain management is strong [46, 98]. 
Karlström and coworkers described that 78% of the women in their study scored 4 or 
more on the NRS scale 24 hours after the surgery. They also reported that unexpected 
pain was an important factor for a negative birth experience [49]. Carvalho et al. 
asked women what they expected before the CS and their biggest concern and fear 
was pain during and after the surgery, followed by nausea and vomiting [97]. There 
are many reasons for ineffective pain management. The patients want to be brave, 
they fear for addiction [46, 99] and they fear that the medication will pass over to the 
baby through the breast milk [97]. Another reason for ineffective pain management is 
that the nurses tend to underestimate the pain of the patient [100-102]. Ineffective 
pain management will also be a hinder for early mobilization and discharge from 
hospital. One third of the women in the study by Karlström et al. believed that their 
ability to breastfeed was affected negatively by postoperative pain [49]. 
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1.12 CLINICAL TRIALS 
The definition of a clinical trial by the Swedish Medical Product Agency (MPA) is a 
study that aims to discover or verify the clinical, pharmacological or 
pharmacodynamic effects of a drug. The trial could also identify any adverse effects, 
study absorption, distribution, metabolism and elimination of the drug, aiming to 
collect information about safety and efficiency of the drug. The MPA has a regulatory 
framework with guidelines about clinical trials, LVFS 2011:19. The main regulatory 
framework with regard to clinical research is the Helsinki Declaration. The 
declaration includes information about informed consent, which is of paramount 
importance. This means that the patient has signed that he/she is aware of the 
potential risks in research and has been informed about study plan e.g. that patients 
are randomly allocated to treatment or placebo [103, 104]. 
A placebo treatment means that the patient receives an inactive drug or a dummy 
treatment. Research has clarified that patients receiving placebo may “respond” to the 
drug or the treatment, a so-called placebo effect. 
The idea of a clinical trial is to compare a control group (no treatment) with an 
intervention group that gets treatment. Most often clinical trials are performed as 
randomized controlled trials (RCT). RCT studies are the golden standard when it 
comes to compare treatment modalities [103-105]. A randomized study means that 
participants are randomly allocated to different groups. The procedure is considered 
to strengthen the study as chance determines who gets active treatment and who gets 
placebo. This means less risk of system errors - bias. To further reduce the risk of 
system failure a blinded study can be performed [103, 104]. 
A clinical trial is divided into different phases. Phase I is when a drug is given for the 
first time to a person. Phase II is normally when a drug is given to a larger group of 
patients suffering from a disease to study how effective the drug is to treat the 
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disease. Phase III is performed on a very large group of patients to conclusively 
define the usefulness of the drug to treat a specific disease. When Phase IIIb is 
performed, the drug is available in the market but new areas of use of the drug are 
tested (in the phase IIIa stage the drug is not yet out on the open market) [103, 104]. 
Study 4 in this thesis was an efficacy study and the definition is: to investigate if A is 
significantly better than placebo or if A is significantly better than B. In the present 
case OXY was compared to IVM/codeine (A versus B). 
Study 1 was a double blind study, meaning that neither the patients nor the attending 
staff had knowledge about which treatment the patient received. Study 4 was a 
randomized study in which women were randomly assigned to different forms of 
treatment, but where both patients and staff were informed about the protocol used. 
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2 AIMS 
The overall aim of this thesis was to investigate additional methods to improve the pain 
therapy in women undergoing cesarean section.  
 
The specific aims of the papers included in the thesis were: 
 
1. To study whether opioid consumption and pain would decrease after a single 
injection of bupivacaine with adrenaline close to the fascia in patients 
undergoing caesarean section in spinal anesthesia (Paper I). 
 
2. To investigate the overall incidence and risk factors for persistent pain 
following caesarean section and to characterize the persistent pain, regarding 
intensity, body location and impact on daily life (Paper II). 
 
3. To study whether a single dose of 20 or 40 ml bupivacaine with adrenaline 
close to the fascia would significantly influence the amount of opioids needed 
to achieve sufficient pain control after caesarean section in general anesthesia 
(Paper III). 
 
4. To investigate if oral oxycodone can provide equal/better and safe postoperative 
pain relief after caesarean section compared to i.v. morphine followed by oral 
codeine (Paper IV). 
 
5. To study the pharmacokinetic aspects of postoperative oxycodone treatment of 
mothers after caesarean section and to investigate possible drug exposure 
through breast milk, including the effects on the newborn (Paper V). 
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3 PARTICIPANTS AND METHODS 
 
3.1 PAPER 1 
Design, setting and participants 
Study I was a randomized double blind controlled study. Two-hundred and sixty 
healthy Swedish-speaking women out of 684 consecutive patients scheduled for CS 
were screened for eligibility and were recruited at the Karolinska University Hospital, 
Huddinge. The inclusion period was between September 1
st
, 2006 and April 30
th
, 
2008. Women who met the inclusion criteria (healthy women, 18-50 years old, 
having a planned CS from 38 completed weeks of gestation) were included. 
Exclusion criteria were ongoing treatment for chronic pain, history of narcotic abuse, 
severe psychiatric history and any intolerance against opioids, local anesthetics or 
other analgesic drugs given in the study. The women had to understand and speak the 
Swedish language. Women were recruited when they visited the clinic for a 
preoperative appointment the day before the CS and they were allocated into one of 
two groups. They gave their verbal and written consent to participate at that time. 
Data collection and methods 
Medical data including demographic data was collected from the computer based 
patient record system Obstetrix™. Pharmaceutical records were secured from the 
computer based patient chart system Take Care™. Primary outcome was morphine 
consumption and secondary variables were pain intensity assessed by NRS and 
mobilization parameters. A blinded local injection of study drug, 40 ml of 
bupivacaine (2.5 mg/ml) with adrenaline (5 µg/ml) (Marcain
®
adrenalin) or 40 ml 
saline solution (0.9%), was administered at the end of surgery before closure of the 
wound by the obstetrician in charge. The injection was located close to and 
immediately above the fascia in the subcutaneous fat. All women had spinal 
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anesthesia and they all got paracetamol, (1g) Perfalgan
®
, as a single i.v. dose after the 
delivery of the baby and thereafter oral administration, 1g every 6th hour, Alvedon
®
, 
combined with i.v. rescue morphine 1.0 mg/ml Morfin MEDA
®
,
 
until NRS estimation 
was at/or below 3 for the first 24 hours after the operation. Thereafter morphine was 
substituted by oral codeine, Kodein Recip
®
, 75 mg every 6th hour. Oral ibuprofen 
400 mg, Brufen
®
, was given as a first dose six hours after the operation and thereafter 
200 mg every sixth hour. Pain assessments were performed when doing uterus 
palpations, at rest and when asking for rescue medication. Mobilization parameters 
were recorded when women were standing next to the bed, walking around in the 
room and when discharged from hospital. Information about surgical site infections 
(SSI) was also collected. 
Statistical methods 
The Mann-Whitney U test was used to analyze demographic data and two tailed 
Student’s t-test to analyze morphine consumption and pain assessment by NRS.  
A power of 80% yields, with a Bonferroni correction for multiplicity, gave a sample 
size estimate of 115 patients per treatment group. To compensate for withdrawals, 
130 patients per arm were recruited. The level of p ≤0.05 was considered significant. 
 
Ethical considerations  
The study protocol was approved by the Regional Ethics Committee in Stockholm, 
Sweden (2006/628-31/1), and the Swedish Medical Products Agency, 
(151:2006/30029). All participants gave their verbal and written informed consent to 
participate in the study. All study records were made anonymous by codification.  
No obvious disadvantage for the participants could be identified as everyone got at 
least the standard treatment. A minor drawback would be that the operation took a 
few minutes longer when injecting local anesthetics or saline. 
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3.2 PAPER 2 
Design, setting and participants  
A prospective long-term follow up study. Out of 260 healthy women from study I 253 
remained for participation in the present study that was performed from September 1
st
 
2006 to April 30
th
 2008. 
Data collection and methods 
Information on demographics, medical history, postoperative pain and analgesic 
requirements was collected through the records in study I. A questionnaire with the 
validated Brief Pain Inventory (BPI) [106] was posted to all women at 3, 6 and 12 
months after the planned CS. A reminder letter was sent out within 3 weeks and a 
phone call was done 5 weeks after mailing the first questionnaire to minimize drop 
outs. Women were asked if they had experienced any pain the last week and if so to 
mark the pain location on a body map. They were also asked to describe pain 
intensity (maximum, minimum and average) and how pain interfered with their daily 
life activities by marking on a NRS. Pain intensities and pain interference with daily 
life were also documented by using the NRS, from 0 no problem at all to 10, very 
large problems. 
Statistical methods 
Demographic data were compared and analysed by Pearson´s Chi-Square test and two 
tailed Student’s t-test. Stepwise multiple logistic regression analysis, with backward 
elimination of possible predictors was used to find possible factors related to long 
term pain at three, six and twelve months. In order to avoid confounders related to the 
pharmacological intervention in study 1 pain at 12-24 hours was used as baseline 
variable. The following covariates were used and analyzed separately: max NRS, 
mean NRS, number of breakthrough pain episodes, parity (0/≥1), previous CS 
(no/yes) and psychological indication (yes/no) for the CS. Significance was 
 45 
 
calculated by Pearson’s Chi Square test. The proportion of women with pain at 3, 6 
and 12 months was compared using the Fischer’s exact test. To evaluate how 
persistent pain influenced parameters related to quality of life, as assessed by BPI, the 
Spearman’s rank test was used. Correction for multiplicity was performed according 
to Bonferroni. The level of p ≤0.05 was considered significant. 
Ethical considerations  
Approval was obtained from the Regional Ethics Committee in Stockholm, Sweden 
(2006/628-31/1), and the Swedish Medical Products Agency, (151:2006/30029). All 
BPI questionnaires were codified with the result that all responses were anonymous.  
 
3.3 PAPER 3 
Design, setting and participants 
A retrospective study based on statistics from CS performed at the Karolinska 
University Hospital, Huddinge. The study included the period between September 1
st 
2008 and June 30
th
 2014. The information was collected from the medical charts 
Obstetrix
®
 and information from 250 undergoing CS in general anesthesia was 
included. 
Data collection and methods 
Five thousand one hundred and ninety three CS were performed at the clinic during 
this time period. The main inclusion criterion was to identify women undergoing CS 
in general anesthesia. There were several exclusion criteria, including any form of 
intrathecal anesthesia, any surgical procedure that could be suspected to markedly 
influence the pain e.g. postpartum hysterectomy, long term pain treatment before the 
surgery, peripartum death of the child, intolerance to drugs involved in the study or 
receiving drug treatment not following the standard protocol. 
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After eliminating all CS with some form of intrathecal anesthesia during delivery the 
number was reduced to 449. After applying the other exclusion criteria, medical 
charts from 250 women remained for further analysis. These were divided into three 
subgroups. There is a recommendation in the department to give local anesthetics 
subcutaneously at the surgical site, close to the fascia (40 ml bupivacaine-adrenaline; 
Marcain
®
adrenalin, 2.5 mg/ml+5 gml). The recommendation was not always 
followed and some surgeons had chosen a lower dose. Seventy-eight records were 
from women receiving local anesthetics of either 20 or 40 ml in the surgical wound 
(36 and 42 women in each group). The control group consisted of 172 records from 
women not receiving any local anesthetics. The primary variable was opioid 
consumption 0-6 hours, 7-12 hours and accumulated 0-12 hours. No data regarding 
pain parameters were available but all patients got i.v. treatment with opioids as 
needed until NRS≤3. Demographic data, as well as information regarding 
perioperative antibiotic prophylaxis, SSI and duration of surgery were collected.  
Statistical methods 
Corrections for multiple comparisons were performed according to Bonferroni. The 
statistics software IBM PASW Statistics, version 18.0, was used to analyze 
differences between groups. Two-tailed Student’s t-test was used for analysis of 
opiate consumption. For demographic data, antibiotic prophylaxis and SSI the 
Pearson’s Chi-Square test was used. A power estimation was made based on results 
from study 1. This estimation suggested that to reach a power of 90% at a 
significance level of P<0.05 we would need 50 women receiving 40 ml bupivacaine-
adrenaline and 50 women not receiving any treatment. As we were not able to recruit 
so many women to the 40 ml group the protocol was modified, i.e. we decided to 
recruit all the eligible patients during the chosen period. In an effort to evaluate 
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whether there was a dose-response relationship we also decided to collect information 
about the group receiving half the amount of bupivacaine-adrenaline. 
Ethical considerations 
The study protocol was approved by the Regional Ethics Committee in Stockholm 
(2012/2225-31-1). All information from patient medical records was codified to 
ensure anonymity. As the information was collected and depersonalized the risk was 
minimal that the patient would consider the study to infringe on the integrity. 
 
3.4 PAPER 4 
Design, setting and participants 
This was a randomized open label parallel group study. Eighty healthy women who 
met the inclusion criteria were recruited at the preoperative visit some days before the 
scheduled CS at the Karolinska University Hospital, Huddinge. The study was 
performed from November 1
st
 2010 to August 30
th
 2012. 
Data collection and methods 
Medical and demographic data were collected from the computer based patient record 
system Obstetrix™. Pharmaceutical records were gathered from the computer based 
patient chart system Take Care™. Two telephone interviews were carried out, the 
first one 5 days postoperatively, to collect information about analgesic intake. 
Ten days postoperatively a structured follow-up telephone interview was performed. 
Women were asked if they still experienced pain and about the location and type of 
pain. They were asked when they ended drug intake or if they still required 
analgesics. Questions also included pain interference with daily life, general 
postoperative recovery, their experience of the CS and of the general care received 
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On the day of discharge, all women received a questionnaire regarding their pain 
experience. The questionnaire included questions related to satisfaction with pain 
management, staffs acceptance of analgesic requirement, understanding of 
instructions regarding their pain treatment and, if applicable, their postoperative pain 
compared to previous CS. At the end of the study a Midwife Global Impression 
(MGI) anonymous questionnaire was handed out to a majority of the midwives 
(n=29/40) working at the maternity ward during the study period. Midwifes' 
experience of the different pain management protocols for pain relief was 
documented.  
Randomization was performed using a computer-based program. Correct medication 
was prepared and ordained in the patient’s records. One hour preoperatively patients 
received 2 g oral paracetamol, Alvedon
®
, as a bolus dose and all women had a spinal 
anesthesia according to local routines. Before leaving the operating room after 
surgery, all patients received oral ibuprofen 400 mg, Brufen
®
. Throughout the rest of 
the hospital stay, all patients received 200 mg ibuprofen every 6
th
 hour.  Oral paraffin 
emulsion (30 ml) was given twice daily to diminish constipation. In the OXY group 
all women received 20 mg long acting OxyContin
®
, as a bolus dose starting 
immediately after surgery. Thereafter 10 mg OxyContin
®
 was given every 12 hours 
for minimum 48 hours. When needed 5 mg immediate release OXY, OxyNorm
®
, was 
administrated as rescue medication, until NRS≤3. If severe breakthrough pain 1-5 mg 
of i.v. OXY, OxyNorm
®
, diluted with 9 ml saline solution was given. In addition 
patients in the OXY group received 1g oral paracetamol every 6
th
 hour until 
discharged. 
The corresponding treatment in the i.v. morphine/codeine group (IVM) was 
morphine, Morfin MEDA
®
, diluted in saline (as needed, until NRS≤3) and 
paracetamol given for the first 24 hours. After that morphine and paracetamol were 
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substituted by a combination treatment of paracetamol 500 mg plus codeine 30 mg, 
Citodon
®
, with a maximum of 8 tablets per day. The oral analgesic treatment 
continued, if needed after discharge, for up to 5 days postoperatively. Women in the 
OXY group received 6 tablets of 10 mg OxyContin
®
. In the IVM group they received 
Citodon
®
, maximum dose eight tablets per day. Both groups were recommended to 
continue with paracetamol/ibuprofen when opioids were no longer required. Citodon
® 
was replaced by paracetamol in the IVM/codeine group. 
Opioid consumption was recorded and converted to oral OXY equivalents. Pain was 
assessed by NRS in different situations and mobilization parameters were also 
recorded. Several safety parameters were collected, including testing of the newborns 
with the Neurological and Adaptive Capacity Score (NACS) method to be able to 
evaluate possible effects of maternal opioid intake. Blood samples from mother and 
newborn as well as breastmilk from the mother were collected and analysed. Side 
effects in the mothers and SSI, if any, were recorded.  
       
Statistical methods 
Two-tailed Student’s t-test was used when comparing NRS, opioid consumption and 
safety variables. For demographic data, interviews and questionnaires the Pearson’s 
Chi-Square test was used. The level of p ≤0.05 was considered significant. 
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Ethical considerations 
The study was approved by the Regional Ethics Committee in Stockholm, Sweden 
(2010/1062-31/1) and the Swedish Medical Products Agency (151:2010/42559). All 
participants gave their verbal and written informed consent to participate in the study. 
All study records were made anonymous by codification. Swedish experience of 
giving OXY for postoperative pain after CS is limited but internationally there is 
considerable experience of OXY treatment. All mothers and children, couples in the 
study were monitored carefully, giving an increased security.  
 
3.5 PAPER 5 
Design and subjects  
The study was designed as a descriptive post-hoc analysis of pharmacokinetic data 
and evaluation of safety. Blood samples and breastmilk samples included in the study 
originated from the OXY treatment group in the randomized trial reported in paper 4. 
Thirty-eight mother-neonate pairs were included in the study. Out of these, evaluable 
PK samples were available in 36 pairs, which constituted the population included in 
the pharmacokinetic analysis. The safety evaluation was based on the 38 mothers and 
their neonates. 
Data collection and methods 
Maternal blood was sampled at 24 and 48 h, neonatal blood at 48 h and breast milk 
was collected at 24 and 48 h, all analyzed for OXY and the metabolites 
noroxycodone, oxymorphone and noroxymorphone using liquid chromatography–
mass spectrometry (LC-MS). Opioid consumption, maternal postoperative pain and 
neonatal adverse effects were observed. Any possible adverse effect of opioids on the 
newborns was evaluated using the NACS score at birth and at 24 and 48 h. The 
assessment is based on 20 criteria in five general areas: adaptive capacity, active and 
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passive tone, primary reflexes and general observations (motor activity, alertness and 
crying). Each item is scored as 0, 1 or 2, adding up to a maximal total score of 40. 
Scores ≥35 indicates a healthy newborn. 
Statistical methods 
The neonate safety variables including NACS, weight development and any aberrant 
observations regarding the newborns were analysed. descriptive analyses and absolute 
changes from baseline were used. The square of the Pearson product-moment 
correlation coefficient (R
2
) was used to quantify the relationship between plasma and 
breast milk concentrations for oxycodone and its metabolites.  
Ethical considerations 
The study was approved by the Regional Ethics Committee in Stockholm, Sweden 
(2010/1062-31/1), and the Swedish Medical Products Agency (151:2010/42559). 
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4 RESULTS 
 
4.1 PAPER 1  
Morphine requirements were significantly less in the bupivacaine group for up  
to 12 h. In the immediate postoperative period, 0-6 h, there were lower mean and 
maximum pain scores by NRS, between the bupivacaine and control groups 
(p≤0.001). When analyzing the number of requests for rescue opioids during the first 
six hours, 47 women in the control group needed five injections or more, compared to 
21 women in the bupivacaine group. Thirteen women in the bupivacaine group 
compared to three in the placebo group never asked for any rescue morphine at all 
during the first six hours postoperatively. This difference in demand for rescue 
medication between bupivacaine and placebo was significant. 
There were no differences between the two groups in time for mobilization or 
discharge from hospital. Two hundred and fifty three (bupivacaine n=128/control 
n=125) women responded to the telephone interview, performed ten days after 
surgery. According to the interview, 128 women expressed that pain relief was as 
they expected and a total of 103 women expressed that pain relief had been quicker 
than expected. The majority of women, 167 stated that the pain was no obstacle in 
their daily life 10 days after the CS. No difference was observed between groups at 
this time point. 
4.2 PAPER 2 
The response rate was high with 91% (231/253) at 3 months, 90% (228/253) at 6 
months and 85% (215/253) answers one year after the CS. At 3 months 56% (52/93) 
of all responders with pain reported pain in and around the surgical site and 32% 
(30/93) of those with pain reported pain on several locations. At 6 months 25% 
(20/63) of the responders with pain reported pain at more than one location on the 
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body map. At that time point 59% (37/63) of the responders with pain marked on the 
body map the pain to be around the surgical site and the corresponding proportion at 
12 months was 26% (12/46). The total number of women with pain localized to the 
abdomen decreased over time from 52 (3 months), to 37 (6 months) and finally to 12 
women (12 months). The percentage of women reporting pain at any body location at 
all 3 time points were 40% (93/231) 3 months, 27% (63/228) 6 months and 21% 
(46/215) 12 months. 
Fourteen women reported abdominal pain at both 3 and 6 months whereas 6 women 
had pain at this location at all 3 time points. Risk factors for persistent pain were 
calculated by multiple logistic regression analysis. The result showed that having a 
first time CS led to a significantly higher risk for persistent pain at 3 and 6 months 
following CS. Surgery performed with psychological indication (maternal request) 
increased the risk for pain at 3 months. Severe postoperative pain or first time CS 
were significant independent risk factors for developing chronic pain for up to 6 
months postoperatively. The most common indications for elective CS were 
psychological/maternal request (36.5%) followed by previous CS (18.1%), breech 
presentation (17.7%) and previous sphincter/perineal rupture (13.1%). 
In the BPI questionnaire we found that parameters related to quality of life were 
impaired in women with persistent pain. There was a significant correlation 
(Spearmans’s rank test) between pain intensity and interference with all seven 
functional domains related to function and quality of life at 3, 6 and 12 months. 
One fourth of all women with pain had sleep problems at 3 months. It would have 
been interesting to know how the frequency of sleep problems would have been if all 
women, even those without pain, had been asked. Quite a few women (22%) reported 
that pain, at all three time points, had an impact on the variable enjoyment of life. 
There was an open ended question in the BPI questionnaire. Many of the responders 
 54 
 
used this as an opportunity to write free comments. Most of the answers were about 
scar pain and/or sensations. At 3 months about 46% (107/231) of all the responders 
used the possibility to make free comments and 13 of the comments regarding scar 
sensations (n=36) were from women with no reported pain. Furthermore, all women 
responding to the open question reported that the scar itched, was numb and/or 
hypersensitive, that clothes worn over the scar were irritating or that they experienced 
a total lack of sensation in the skin around the surgical site. At 6 months 34% 
(77/228) of the responders wrote free comments. Scar sensation (n=25) was still the 
most frequent topic, followed by mobility (n=19) and pain (n=19). Twelve months 
after the CS, 30% (65/215) of the responders used the free comments. Remarks about 
pain (n=21) followed by comments about mobility (n=15) and scar sensations (n=10) 
were most frequent Fig. 1. At 12 months the questionnaire was also spontaneously 
used by the responders’ to “close the study and the CS”, i.e. as a summary. There 
were 23 comments about wellbeing, satisfaction with the CS and/or with treatment in 
the maternity ward. 
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Figure 1. Free comments from women in the different time points were categorized 
into 9 different categories.  
 
4.3 PAPER 3 
There was a significant lower BMI in the group receiving 20 ml bupivacaine than in 
the two groups, otherwise there were no other differences regarding demographics. 
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A significantly lower opioid consumption was found during the first 0-6 h following 
CS in women receiving 40 ml bupivacaine-adrenaline in the surgical site when 
compared with controls (p≤0.05). No such difference was seen with the 20 ml group.  
There were no significant differences between the two “treatment groups” found at 
any of the periods analyzed. The most common indication for emergency CS at our 
department was fetal distress. Nearly 93% of those who should have prophylactic 
antibiotic treatment according to the routine protocol got it. Surgical site infections 
were rare with a total of 7, all groups included and all of them had received 
prophylactic antibiotic treatment. No significant difference in SSI was seen when 
controls were compared with all patients receiving local anesthetics. 
 
4.4 PAPER 4 
Eighty women were recruited (40+40). Two women in the OXY group and one 
woman in the control group had to be excluded. There was significantly lower pain 
intensity when asking for rescue medication in the OXY group than in the 
IVM/codeine group the first 24 h following CS. Provoked pain (uterus palpation)  
0-6 h was also less in the OXY group. 
There were, however, no differences between the groups when looking at opioid 
consumption or mean pain intensity at rest (0-24 h). Both pain intensity and opioid 
consumption were lower in the OXY group 25-48 h post CS. It took significantly less 
time to administered OXY than IVM/codeine. We found no serious adverse effects 
among women in any of the groups although the number of common opioid adverse 
effects was higher with IVM/codeine. No adverse outcomes in the newborns related 
to treatment were observed in either group. 
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When answering the questionnaire on the day of discharge most women (76/80) 
experienced adequate pain alleviation and were satisfied with pain management. Ten 
women (four in the OXY group and six in the IVM/codeine group) reported 
unsatisfactory pain relief. Despite this, all women told that they gained support for 
their reported need to relieve the pain and they understood instructions about pain 
treatment. On postoperative day 10 analgesics requirements were low and similar 
between groups. Women in the OXY group experienced a greater well-being than in 
the IVM/codeine group (100% vs. 87%; not significant) and reported pain as less of 
an obstacle than in the IVM/codeine group (79% vs. 51%; p=0.011). The care in 
connection with the CS and at the maternity ward was perceived as positive or very 
positive. All midwifes (n=49) receiving the MGI questionnaire responded. Most of 
them judged the OXY group patients to have less pain (93.1%; 6.9% considered 
treatments equal) and that the women were easier to mobilize (88.9%; 11.1% thought 
it was the same). A majority of the staff (79.3%) judged patient contentment with 
analgesic treatment to be better in the OXY group while 20.7% considered protocols 
equal. A majority perceived workload to be less with OXY treatment while others 
judged it as similar (72.4% vs 27.6%). Most midwifes (93.1%) apprehended oral drug 
administration (OXY) as less time consuming than i.v. injections (IVM), which was 
confirmed by the time study.  
 
4.5 PAPER 5 
All 36 mothers with plasma samples had detectable OXY levels and achieved 
adequate pain relief. Thirty-three mothers had quantifiable levels of noroxycodone 
and noroxymorphone. Only one mother had a quantifiable oxymorphone 
concentration in the plasma. 
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Several milk samples were excluded due to small amounts or other reasons associated 
with laboratory analysis. Breastmilk samples at 24 hours could be analysed in 14 
mothers. Thirteen women had quantifiable OXY levels, in 12 noroxycodone could be 
detected and in 10 women noroxymorphone was found. No woman had a quantifiable 
level of oxymorphone.  
At 24 hours postoperatively 11 mothers had quantifiable levels of OXY and 
noroxycodone in both plasma and breastmilk. When analyzing noroxymorphone 8 
mothers had quantifiable levels in both plasma and breast milk. 
At 48 hours quantifiable levels of OXY were observed in plasma and breastmilk from 
18 mothers. Fourteen mothers had measurable levels of noroxycodone in both plasma 
and breast milk and there were 10 mothers who had quantifiable levels of 
noroxymorphone in plasma and breast milk. 
Blood samples from 36 newborns were collected but only four had quantifiable OXY 
concentrations. In 16 children no oxycodone could be detected at 48 hours. Eleven 
samples could not be analysed due to technical difficulties. One sample had an 
inferring peak and the remaining four children had oxycodone levels below the limit 
of quantification. In the four neonates with detectable plasma concentrations of OXY, 
NACS scores at 0, 24 and 48 hours were within the normal ranges. One neonate had a 
high oxycodone plasma level of 232, a result the accuracy of which was questioned as 
the NACS scores indicated a normal status. Several factors indicate the incorrectness 
in the value as it would involve large amounts of breast milk, and a large drug intake 
in the mother, which was not present in this case. This result may be questioned and 
the likely explanation is an erroneous result in the chemical analysis. 
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One neonate developed a pulmonary adaptation disturbance (PAS) at 24 hours 
detected by the NACS and the baby was transferred to the NICU. This neonate had no 
detectable OXY plasma concentration.  
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5 DISCUSSION 
 
5.1 METHODOLOGICAL CONSIDERATIONS 
The first study in this thesis started, in the beginning of September 2006 and the last 
one ended in August 31
th
 2014, which means 8 years of data collection.  
Studies included in the thesis mainly constitute a quantitative approach but in some 
cases qualitative methods are involved. Statistical calculations were used to analyze 
the quantifiable results such as morphine consumption, mobilization and pain 
parameters. The qualitative data was collected through interviews and open-ended 
questions in the questionnaire and the material was then analyzed. 
To investigate the differences between the groups in study 1 and 4 a randomization 
was performed. A strength of the studies included in this thesis is the large number of 
participants and the high response rate. However, a limitation was identified in study 5 
since many samples could not be analyzed due to problems in the laboratory. 
Nevertheless, the results of the latter study are still important because it adds new 
information to studies previously published. 
There was few data missing and a low number of withdrawals in all studies. The 
protocols for pain treatment and the study protocols were rigorously followed by the 
staff. The high compliance may be due to a small group of investigators working 
closely together with the ward staff. Daily monitoring and interested coworkers are 
also central for reliability and high quality of study results.  
In study 2 there was a lack of information about pre-operative pain and other factors 
e.g. genetics and preexisting anxiety or other psychological aspects that would have 
been interesting to investigate. A strength of study 2 compared to other publications 
regarding long-term follow-up was that it minimized the recall bias as the women did 
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not have to recall the postoperative pain. The first set of data was collected in close 
connection to the CS. 
There are limitations when conducting a register based study as in study 3 as there is 
no possibility to affect the background information and one has to trust the material. 
A strenght of the study was that few parameters were investigated and that 
information was collected during pregnancy and in close connection to the surgery. 
A double blinded randomized study would have been the best choice for study 4 but 
the reason for not using this method was the ethical aspect of collecting blood 
samples from all the newborns as well as milk samples from the mothers. When 
choosing not perform a double blinded study the sampling could be limited to the 
OXY group, which we considered to be more important as there is less data about this 
opioid. There were no drop outs due to allocation to either group. In connection with 
routine blood sampling for PKU an extra blood sample was collected which did not 
result in any additional pain to the child. 
Another limitation to this study was that we never did any CYP2D6 
pharmacogenomics analyses, and therefore some women in the IVM/codeine group 
might have been slow metabolizers, not responding to codeine, affecting their 
response to treatment. NACS evaluation was found to be a valuable tool in this study 
and was performed only by two trained persons. 
It is an ethical question to sample colostrum from new mothers for pharmacokinetic 
analysis, although all mothers accepted. The benefits of the knowledge about how 
OXY works in lactating mothers was considered greater than eventual disadvantages. 
One major challenge in this study was the small samples of breastmilk in the first  
24 h as some breast milk samples had to be diluted before analysis. This has 
contributed to some uncertainty regarding interpretation of the results. There were 
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also some problems with samples that could not be evaluated due to technical 
problems with the chemical analysis. 
 
5.2 DISCUSSION OF THE RESULTS 
The frequency of CS increases globally and care around CS is a dynamic process as 
surgical methods and anesthetics change and improve over time. Studies included in 
this thesis extend over a number of years and much has happened in the pain 
management field during this period. Studies included in the present thesis has 
investigated pain associated with CS from different perspectives, investigated several 
forms of pain management methods related to the CS and evaluated in what way pain 
affects women in both the short and the long term. There are high demands on the 
staff as it is important to offer methods for pain relief that as little as possible affects 
the newborn through the breast milk. The new mother also needs to be confident 
about the protocol and not refrain from accepting analgesia due to fear that it will 
affect the baby. It is necessary to identify various efficient CS pain management 
methods that can be used in different settings, both in low income and high income 
countries. It is important that all women undergoing a CS should have the best 
possible chance for a good start with the newborn. This means that no matter where 
women live in the world they should have access to an efficient pain treatment 
following CS.  
In general multimodal analgesia is the best way to relieve pain postoperatively. This 
is even more relevant when it comes to CS as the pain is a combination of visceral 
pain due to uterus contractions and nociceptive pain due to surgery. Both oral 
administration of opiates and local anesthesia represent ways to improve pain 
management.  
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In study 1 and 3 the results showed that local anesthetic in the surgical site decreased 
postoperative opioid consumption and was an easy way to improve pain control. 
Some studies have been performed investigating local injection of anesthetics in 
connection with CS and the review by Bamigboye and Hofmeyr’s [57] as well as a 
study by Ranta and coworker [56] confirm the findings in study 1 and 3. Studies have 
shown [23, 29, 30] that worry and anxiety aggravates the pain. After CS in general 
anesthesia women often wakes up without any form of pain relief. Concerns about the 
situation and unawareness of what has happened to her and to her child can affect the 
pain negatively. The greatest benefit for local analgesia is that it can be initiated 
before ending the general anesthesia, which can improve postoperative pain control. 
The new mother should not have to deal with both maximum pain and anxiety at the 
same time. According to study 1 local anesthetic in the surgical wound contributes to 
analgesia for at least 6 hours postoperatively and there is time for additional pain 
treatment to be initiated. Local anesthesia is an easy procedure and is a simple 
alternative to more invasive methods.  
Study 4 was conducted to evaluate if oral administration of a potent opioid would be 
beneficial after CS compared to i.v. morphine followed by oral codeine. Several 
studies during the last years have reported about adverse effects and even death in 
newborns where the mothers were on codeine medication while nursing [93-95]. Due 
to differences in codeine metabolism the bioavailability is difficult to predict. This 
was the main reason to investigate and consider the option to phase out codeine from 
the standard medication at clinic at Karolinska University Hospital. The choice of 
oral OXY instead of oral morphine was motivated by its good and less variable 
bioavailability (19-47% vs 67-80%), further reducing the interindividual variability 
[69, 107]. 
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The comparison between intake of parenteral morphine and oral OXY was in general 
favorable for latter. Several different parameters were analyzed related to the safety 
of the mother and her newborn. The present study did not identify any safety risks in 
any of the groups when women were treated for only a short period after CS. 
However, to be conclusive concerning safety a study would have had to include many 
more patients but our results add valuable information to previous studies and the 
accumulating clinical experience of using OXY. Take together we suggest that OXY 
is an excellent choice of opioid when compared with the previously used schedule, 
especially as the oral administration worked very well. 
Another experience from the study was that the NACS assessment turned out to be a 
useful tool to evaluate the newborns. On a number of occasions morbidity, like e.g. 
PAS in the baby was early identified and it is reasonable to assume that diagnosis 
otherwise would have been delayed. Above all, it was the parts of the NACS 
assessment concerning active and passive tone that in the current setting turned out to 
be most effective in finding babies at risk. 
Study 5 fills a gap in the current knowledge about how OXY and its metabolites are 
excreted in serum and milk and how it passes over to the baby. An additional strength 
of this study is that the possible impact of OXY on the baby has been studied and 
verified by NACS scores and other safety variables. The purpose of the study was 
similar to a study by Seaton and coworkers [89]. However, in the previous report only 
the parent compound OXY was investigated and less data on the potential impact on 
the newborns was presented. It is important to explain to the newly delivered mother 
that early after CS only small amounts of OXY passes over to the baby through breast 
milk.  Drug levels in blood and breast milk are usually at most the first 24 h but BMT 
has been shown to be delayed following CS. Furthermore, milk production is low and 
in fact very small amounts of the drug are passing over. 
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It appears clear that an effective pain relief reduces the risk for chronic pain after CS. 
Study 2, confirmed already existent evidence [24, 37, 39, 40] that severe 
postoperative pain is associated with chronic pain. However, no other studies have 
been found reporting that psychological indication, maternal request, as well as 
having a first CS would increase the risk of pain. When conducting study 2 the 
hypotheses was that numerous CS would enhance the risk of pain because of the 
increased risk of adhesions, which could not be confirmed in the study. To make 
women aware of the importance of sufficient pain relief it could be valuable to 
consider informing about risk factors for long term pain before the CS, thereby 
increasing their motivation to demand the best possible pain control. It could also be 
reasonable to inform women about these risk factors when they ask for a CS without 
any strictly medical reason. 
Today, most women have a spinal anesthesia with the addition of morphine at CS. 
This has been shown to provide an exceptionally good pain relief also 
postoperatively, with minimal need for intravenous or oral opioids. For women 
undergoing caesarean section under general anesthesia, there is still a pronounced 
need for multimodal treatment. The strategies we have studied, local anesthesia in the 
surgical wound and oral treatment with OXY, can improve pain relief in these 
women. 
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6 CONCLUSIONS AND FURTHER DIRECTIONS 
 
 Local anesthetic in the surgical wound is an easy and efficient tool for pain 
management. It is opioid-saving and will contribute to pain control in the 
immediate postoperative period where other strategies for pain relief can be 
initiated.  
 
 Since intrathecal anesthesia including morphine now has become the golden 
standard for pain relief at CS it can be assumed that the greatest benefit of local 
anesthesia would be apparent when the operation is performed in general 
anesthesia.  
 
 Severe postoperative pain increases the risk for persistent pain after CS.  
Increased risk for long term pain was also present at a first time CS, and if the 
indication for CS was maternal request. 
 
 It is an open question how women should be informed about the risk of 
persistent pain after CS. One reason to inform about the risk would be to point 
out that women always should ask for adequate pain medication and thereby 
possibly reducing this risk. It is also reasonable to inform women when asking 
for CS without any medical reasons (maternal request) about the long term 
consequences. 
 
 The result shows that oral OXY compared to i.v. morphine and codeine was an 
effective and safe treatment of pain in the first days after the CS. Only minor 
adverse effects of opioid intake were found in the mothers and none in their 
babies. The amounts of OXY or its metabolites were excreted from the woman 
to the baby through breast milk in such small quantities that it cannot be 
expected to affect the child when used only for a few days after delivery.  
 
 Constipation is a general problem when using opiates. There is another choice 
available today for oral opiate treatment, i.e. OXY plus naloxone (Targiniq
®
, 
Mundipharma). To our knowledge no studies regarding this drug in connection 
with postoperative pain control after CS has yet been published.   
 
In the future the following aspects regarding research as well as clinical topics should 
be addressed: 
 
 Prospective studies investigating not only the need for opiates but also pain 
and mobilization parameters after CS in general anesthesia, in connection 
with local anesthesia. 
 
 To investigate if the combination of OXY and naloxone could improve 
postoperative treatment after CS by diminishing the problems with 
constipation. 
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 To perform prospective studies aiming to investigate severe postoperative 
pain and the risk for persistent pain, including how preoperative pain can 
influence the process. 
 
 T inform both care givers and women facing a CS about how pain 
assessment and pain relief works, why it is so important both in the short 
and long term perspective, to be pain relieved and guide women about when 
to ask for medication. 
 
 The new mother should also be informed that most drugs used in 
connection with delivery can be taken during breastfeeding. This is 
important because many new mothers do not take enough medication 
because of concern for transmission to the baby through breast milk. 
 
 The care givers should be continuously informed about the mechanisms 
behind pain how pain relief works and why it is so important to listen to and 
rely on the woman's description of her pain. 
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7 SVENSK SAMMANFATTNING 
 
Kejsarsnittfrekvensen ökar i hela världen och på en del kliniker är hälften av alla 
förlossningar ett kejsarsnitt. I Sverige har siffran i flera år legat strax under 20%. 
Läkemedel och olika behandlingsmöjligheter förbättras hela tiden och dagens 
sjukvård kan erbjuda ett flertal olika alternativ. Samlade forskningsresultat talar för 
att ett multimodalt synsätt ger de bästa förutsättningarna för smärtbehandlingen efter 
ett kejsarsnitt. Det innebär att man kombinerar olika former av läkemedel och 
administrationssätt för att kunna behandla olika former av smärta varvid man kan 
undvika att ge för stora mängder av de enskilda läkemedlen. På så sätt minskar man 
också risken för biverkningar. När det gäller behandlingen av operationssmärta efter 
ett kejsarsnitt ställs det extra höga krav på läkemedel då det är olika former av smärta, 
dels från operationssåret och dels från livmoderns sammandragningar. Det är också 
viktigt att använda läkemedel som den nyblivna mamman samt vårdpersonal kan 
känna sig trygga med, då det inte skall påverka barnet med tanke på överföring av 
läkemedlet via amningen.  
Det är viktigt att underlätta både amning, anknytning mellan mor och barn och 
mobilisering, vilket kräver en så smärtfri postoperativ period som möjligt.  Det 
övergripande syftet med avhandlingen var att undersöka hur smärtlindringen hos 
kvinnor som genomgår ett kejsarsnitt kan förbättras. De fem olika studierna som 
ingår i avhandlingen har på olika sätt haft som syfte att belysa hur smärtan ur olika 
perspektiv påverkar kvinnan och hennes barn. 
I arbete 1 studerades om lokalbedövning i operationssåret skulle innebära några 
fördelar för kvinnan. En randomiserad studie genomfördes där den ena gruppen fick 
lokalbedövning i operationssåret och den andra gruppen fick koksaltlösning. 
Resultatet visade att lokalbedövningen (bupivakain-adrenalin) minskade behovet av 
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morfin efter operationen och att dessa kvinnor hade mindre ont. I studie 2 följde vi 
kvinnorna från studie 1 vid tre olika tillfällen upp till ett år efter kejsarsnittet. Vid 3, 6 
och 12 månader skickade frågeformulär ut om eventuell kvarstående smärta och hur 
denna smärta påverkade kvinnorna i deras dagliga liv. Kvinnorna fick också beskriva 
smärtans lokalisation och vilken typ av smärta det rörde sig om. Vid 3 månader hade 
40% av kvinnorna ont och vid 6 och 12 månader var motsvarande siffra 27% och 
21%. Många gånger hade kvinnorna ont på fler än ett ställe på kroppen och smärtan 
påverkade dem i deras dagliga liv. Vid 3 månader visade resultatet att både kejsarsnitt 
på psykologisk indikation (kvinnans begäran) och ett första kejsarsnitt ökade risken 
för långvarig smärta. Vid 6 månader fann vi att svår postoperativ smärta ökade risken 
och även här innebar ett första kejsarsnitt en riskökning med avseende på långvarig 
smärta.  
I den tredje studien gjordes en journalgranskning på kvinnor som genomgått ett 
kejsarsnitt i narkos på sjukhuset sedan 2008. Syftet var att undersöka 
morfinförbrukningen hos de kvinnor som fått lokalbedövning (20 eller 40 ml 
bupivacain-adrenalin) i operationssåret i samband med kejsarsnittet jämfört med 
kontroller som inte fick denna behandling. Även denna studie visade att det fanns ett 
minskat behov av opioider hos gruppen som fått 40 ml lokalbedövning men ingen 
signifikant effekt hos gruppen som fått 20 ml.  
I den näst sista studien, studie 4, undersöktes om oralt oxykodon (OXY) var ett säkert 
och lika bra eller bättre läkemedel jämfört med intravenöst (i.v.) morfin följt av oralt 
kodein. Alla kvinnor fick även paracetamol och ibuprofen. Opioidförbrukningen var 
signifikant mindre i OXY gruppen, liksom den skattade smärtan hos kvinnorna. 
Biverkningarna hos mödrarna, dock lindriga sådana, var signifikant fler i 
morfin/kodeingruppen. Tiden att administrera läkemedlen jämfördes och det gick 
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signifikant fortare att dela ut OXY- tabletter än att spruta i.v. morfin. Det var inga 
skillnader mellan grupperna när det gällde säkerhetsaspekter för barnen. 
Studie 5, var en farmakokinetik studie. Serum och bröstmjölk från de kvinnor som 
ingick i OXY gruppen i studie 4 samt serum från deras barn analyserades med 
avseende på OXY och dess metaboliter (noroxycodone, oxymorphone and 
noroxymorphone).  
Det fanns detekterbara mängder av OXY i alla kvinnors serum och hos de flesta var 
även noroxykodon och norxymorfon mätbara. Mätbara nivåer av OXY och dessa två 
metaboliter kunde i de flesta fall även identifieras i den bröstmjölk som gick att 
analysera. I de allra flesta fall fanns låga eller icke mätbara mängder OXY i barnens 
blod. Inga biverkningar eller patologiska NACS-bedömningar som kunde härledas till 
opioidbehandlingen av mödrarna sågs hos något av barnen. 
Sammafattningsvis är lokalbedövning i operationssåret en enkel behandlingsform 
både vid kejsarsnitt i spinalbedövning och vid kejsarsnitt i narkos. Även oral 
behandling med OXY är en effektiv behandling där de aktuella studierna inte kunnat 
identifieras några negativa effekter hos mödrarna eller hos det nyfödda barnen.  
Bägge behandlingsformerna, lokalbedövning och oralt OXY minskar opiatbehov och 
postoperativ smärta. En mindre mängd opioider kan förväntas minska risken för 
biverkningar och minskad smärta kan bidra till att minimera risken för långvarig 
smärta efter kejsarsnitt. De strategier som har studerats i denna avhandling, 
lokalbedövning i operationssåret och tablettbehandling med OXY, kan vara till god 
hjälp för att tillgodose behovet av postoperativ smärtlindring hos framför allt de 
kvinnor som genomgår kejsarsnitt i narkos. 
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